Bradley Monk, MD, FACOG, FACS, clinician at Arizona Oncology, shares his experience mitigating the potential side effects of PARP inhibitors in ovarian cancer treatment.
Bradley Monk, MD, FACOG, FACS, clinician at Arizona Oncology, professor at the University of Arizona and Creighton University in Phoenix, shares his experience mitigating the potential side effects of PARP inhibitors in ovarian cancer treatment.
Transcript
Are there any practices physicians should ensure are implemented to ensure the best possible patient outcomes during treatment with PARP inhibitors?
When you utilize PARP inhibitors, I think it's important to have a multidisciplinary team. That will sort of depend on your scenario. It could include a physician's assistant or a nurse practitioner, patient navigator, or even a pharmacist. But together, monitoring is important. We monitor the blood counts once a week generally, especially in niraparib if the platelet count begins to fall less than 100, we stop and recover. We also monitor for GI disturbances, and certainly fatigue. GI disturbances are something that you're very familiar with, you can sort of mitigate the nausea or the diarrhea. But if your land subpoena ondansetron or imodium is not working, you should stop, and recover, and then dose reduce. Fatigue is a little bit more complicated because fatigue can be due to lots of things—sleep deprivation, depression, malnutrition, dehydration, hypothyroidism, and anemia. You've got to make sure that you have the attribution, the cause of the fatigue, right before you treat it. So we have an algorithm that can inform that. But I think you have to have an understanding of monitoring the adverse reactions and the mitigation strategies of these very active, particularly in the molecularly defined subsets, oral anti-cancer therapies.
Study Links COVID-19 Pandemic to Rise in Neoadjuvant Chemotherapy for Ovarian Cancer in US
April 17th 2024There was greater use of neoadjuvant chemotherapy among US patients with ovarian cancer (OC) during the COVID-19 pandemic to reduce potential COVID-19 exposure and cancer treatment-related complications.
Read More
Most Patients With Mucinous Ovarian Cancer Don't Need Perioperative GI Endoscopy
April 12th 2024A new study suggests routine gastrointestinal (GI) endoscopy is not needed for most patients with mucinous ovarian cancer in the perioperative setting due to a lack of statistically significant overall survival benefits.
Read More
Model Including Diffusion-Weighted MRI More Accurately Predicts Ovarian Cancer Resectability
April 4th 2024A recent study suggests a modified model incorporating diffusion-weighted MRI can more accurately predict ovarian cancer primary debulking surgery outcomes compared with the standard, widely used Memorial Sloan Kettering Cancer Center risk model.
Read More
Patients Treated With Mirvetuximab Soravtansine vs Chemotherapy Report Better HRQOL
March 29th 2024An abstract presented at the 2024 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer explored patient-reported health-related quality of life (HRQOL) among patients treated with mirvetuximab soravtansine compared with standard chemotherapy.
Read More
Mirvetuximab Soravtansine-gynx Granted Full FDA Approval for FRα+ Platinum-Resistant Ovarian Cancer
March 22nd 2024Mirvetuximab soravtansine-gynx (Elahere) received full FDA approval for the treatment of folate receptor alpha–positive (FRα+), platinum-resistant ovarian cancer (PROC) based on findings from the confirmatory phase 3 MIRASOL trial.
Read More